Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

Jiangsu Hengrui Pharmaceuticals (JHPCY) has registered zero cyber incidents and zero material red-flag 8-K filings over the past 90 days, suggesting baseline operational stability in our recent detection window. However, low signal in a 90-day window does not indicate low structural risk; the pharmaceutical sector faces persistent dilution and financing pressures that require deeper historical context. The full $49 Report extends analysis to 12 months of SEC filings, quantifies dilution risk across cap table changes, maps financing history and covenant exposure, and applies AI-driven risk signals specific to biotech capital structures. The full $49 Report adds dilution risk scoring, 12-month 8-K context, financing trajectory analysis, and sector-specific AI risk flags.